Next to alterations of HLA class I antigens, high expression levels of co-inhibitory checkpoints, such as e.g., PD-L1 and B7-H4, in various tumor entities are often associated with the clinical outcome of cancer patients (85–88). The gene discussed is CD274; the disease is cancer.